Sonoma Pharmaceuticals Inc (SNOA)

Name: Sonoma Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Drug Manufacturers Specialty Generic

Latest reporting period: 2025-09-30

Latest Quarter

2025-09-30

Revenue

$5.6M

Net Income

-$534K

Operating Margin

-6.0%

Free Cash Flow

-$168K

Debt / Assets

67.8%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Sonoma Pharmaceuticals Inc (SNOA).
Income Statement (Quarterly)	2025-09-30	2025-06-30	2024-12-31	2024-09-30
Revenue	5,604,000	4,015,000	3,564,000	3,579,000
Cost of Revenue	3,484,000	2,551,000	2,294,000	2,218,000
Gross Profit	2,120,000	1,464,000	1,270,000	1,361,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,882,000	1,965,000	1,874,000	1,705,000
Operating Expenses	2,457,000	2,559,000	2,301,000	2,211,000
Operating Income	-337,000	-1,095,000	-1,031,000	-850,000
Interest Expense	0	0	0	0
Income Before Tax	-731,000	-1,242,000	-919,000	-463,000
Income Tax Expense	-197,000	-1,000	9,000	147,000
Net Income	-534,000	-1,241,000	-928,000	-610,000
Per Share
EPS	-0.32	-0.76	-0.63	-0.59
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Sonoma Pharmaceuticals Inc (SNOA).
Income Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Revenue	14,288,000	12,735,000	13,272,000	12,628,000	18,629,000
Cost of Revenue	8,823,000	7,990,000	8,795,000	8,635,000	12,070,000
Gross Profit	5,465,000	4,745,000	4,477,000	3,993,000	6,559,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	7,361,000	7,575,000	8,840,000	9,755,000	9,453,000
Operating Expenses	9,175,000	9,446,000	9,047,000	9,880,000	10,008,000
Operating Income	-3,710,000	-4,701,000	-4,570,000	-5,887,000	-3,449,000
Interest Expense	0	0	16,000	-10,000	12,000
Income Before Tax	-2,907,000	-5,031,000	-5,184,000	-5,418,000	-3,902,000
Income Tax Expense	550,000	-196,000	-33,000	-332,000	713,000
Net Income	-3,457,000	-4,835,000	-5,151,000	-5,086,000	-3,950,000
Per Share
EPS	-2.79	-5.32	-15.18	-1.92	-1.97
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Sonoma Pharmaceuticals Inc (SNOA).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Cash and Cash Equivalents	5,374,000	3,128,000	3,820,000	7,396,000
Short Term Investments	0	0	0	0
Net Receivables	3,763,000	2,898,000	6,417,000	4,778,000
Inventory	2,915,000	2,719,000	2,858,000	2,663,000
Total Current Assets	12,648,000	12,548,000	13,798,000	16,430,000
Property Plant Equipment	309,000	651,000	906,000	879,000
Goodwill and Intangibles	0	0	0	0
Total Assets	13,693,000	14,740,000	16,231,000	18,845,000
Liabilities
Account Payables	953,000	607,000	841,000	1,641,000
Short Term Debt	278,000	521,000	687,000	1,058,000
Total Current Liabilities	4,096,000	3,719,000	3,717,000	5,819,000
Long Term Debt	27,000	87,000	162,000	309,000
Total Liabilities	9,282,000	8,603,000	8,254,000	10,148,000
Shareholders Equity
Retained Earnings	-197,806,000	-194,349,000	-189,514,000	-184,363,000
Total Shareholders Equity	4,411,000	6,137,000	7,977,000	8,697,000

Balance sheet annual history for Sonoma Pharmaceuticals Inc (SNOA).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Assets
Cash and Cash Equivalents	5,374,000	3,128,000	3,820,000	7,396,000	4,220,000
Short Term Investments	0	0	0	0	0
Net Receivables	3,763,000	2,898,000	6,417,000	4,778,000	4,656,000
Inventory	2,915,000	2,719,000	2,858,000	2,663,000	2,530,000
Total Current Assets	12,648,000	12,548,000	13,798,000	16,430,000	12,983,000
Property Plant Equipment	309,000	651,000	906,000	879,000	1,129,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	13,693,000	14,740,000	16,231,000	18,845,000	14,987,000
Liabilities
Account Payables	953,000	607,000	841,000	1,641,000	1,769,000
Short Term Debt	278,000	521,000	687,000	1,058,000	836,000
Total Current Liabilities	4,096,000	3,719,000	3,717,000	5,819,000	4,078,000
Long Term Debt	27,000	87,000	162,000	309,000	1,839,000
Total Liabilities	9,282,000	8,603,000	8,254,000	10,148,000	9,624,000
Shareholders Equity
Retained Earnings	-197,806,000	-194,349,000	-189,514,000	-184,363,000	-179,277,000
Total Shareholders Equity	4,411,000	6,137,000	7,977,000	8,697,000	5,363,000

Cash flow quarterly history for Sonoma Pharmaceuticals Inc (SNOA).
Cash Flow Statement (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Activities
Net Income	-3,457,000	-4,835,000	-5,151,000	-5,086,000
Depreciation & Amortization	138,000	176,000	125,000	186,000
Stock Based Compensation	224,000	516,000	669,000	382,000
Change in Working Capital	2,476,000	1,693,000	-1,864,000	3,131,000
Operating Cash Flow	-88,000	-2,398,000	-6,152,000	-4,248,000
Investing Activities
Capital Expenditure	-80,000	-17,000	-269,000	-137,000
Investments	-80,000	-17,000	-269,000	-137,000
Investing Cash Flow	-80,000	-2,000	-258,000	-99,000
Financing Activities
Debt Repayment	-404,000	-481,000	-120,000	-497,000
Common Stock Issued/Repurchased	3,078,000	1,784,000	2,868,000	7,554,000
Dividends Paid	0	0	0	0
Financing Cash Flow	3,030,000	1,676,000	2,489,000	7,396,000
Summary
Free Cash Flow	-168,000	-2,415,000	-6,421,000	-4,385,000
Net Change in Cash	2,246,000	-692,000	-3,576,000	3,176,000

Cash flow annual history for Sonoma Pharmaceuticals Inc (SNOA).
Cash Flow Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Operating Activities
Net Income	-3,457,000	-4,835,000	-5,151,000	-5,086,000	-3,950,000
Depreciation & Amortization	138,000	176,000	125,000	186,000	227,000
Stock Based Compensation	224,000	516,000	669,000	382,000	371,000
Change in Working Capital	2,476,000	1,693,000	-1,864,000	3,131,000	1,384,000
Operating Cash Flow	-88,000	-2,398,000	-6,152,000	-4,248,000	-3,378,000
Investing Activities
Capital Expenditure	-80,000	-17,000	-269,000	-137,000	-179,000
Investments	-80,000	-17,000	-269,000	-137,000	-179,000
Investing Cash Flow	-80,000	-2,000	-258,000	-99,000	388,000
Financing Activities
Debt Repayment	-404,000	-481,000	-120,000	-497,000	-481,000
Common Stock Issued/Repurchased	3,078,000	1,784,000	2,868,000	7,554,000	0
Dividends Paid	0	0	0	0	0
Financing Cash Flow	3,030,000	1,676,000	2,489,000	7,396,000	3,308,000
Summary
Free Cash Flow	-168,000	-2,415,000	-6,421,000	-4,385,000	-3,557,000
Net Change in Cash	2,246,000	-692,000	-3,576,000	3,176,000	529,000